MAPK9 and breast carcinoma: JNK2 correlates with decreased disease-free survival in breast cancer patients diagnosed with the Basal-like subtype [29], increases epithelial to mesenchymal transition (EMT) [30], and JNK2 knockdown reduces lung metastasis of mammary cancer cells [24].